These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26316013)

  • 1. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
    Curtis JR; Churchill M; Kivitz A; Samad A; Gauer L; Gervitz L; Koetse W; Melin J; Yazici Y
    Arthritis Rheumatol; 2015 Dec; 67(12):3104-12. PubMed ID: 26316013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
    Saraux A; Flipo RM; Fagnani F; Massol J; Cukierman G; Joubert JM; Huot-Marchand P; Combe B
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Curtis JR; Herrem C; Ndlovu 'N; O'Brien C; Yazici Y
    Arthritis Res Ther; 2017 Sep; 19(1):215. PubMed ID: 28962590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
    Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
    Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
    Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
    BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
    Combe B; Furst DE; Keystone EC; van der Heijde D; Luijtens K; Ionescu L; Goel N; Emery P
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):299-307. PubMed ID: 26238672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
    Weinblatt ME; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; VanLunen B; Ecoffet C; Cioffi C; Emery P
    Arthritis Rheumatol; 2017 Oct; 69(10):1937-1948. PubMed ID: 28666080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
    Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
    Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
    Blanco FJ; Rubio-Romero E; Sanmartí R; Díaz-Torné C; Talavera P; Dunkel J; Naredo E;
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):345-352. PubMed ID: 30236749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
    Burmester G; Nüsslein H; von Hinüber U; Detert J; Richter C; Kumke T; Leunikava I; Lendl U; Fricke D; Müller-Ladner U
    Clin Exp Rheumatol; 2019; 37(5):842-851. PubMed ID: 30873942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.